adjusting for age, gender, diabetes, hypertension, tobacco use, and hyperlipidemia. Of particular importance, severe psoriasis conferred an additional 6.2% absolute risk of 10-year major adverse cardiac events. 10 Finally, a meta-analysis of 9 studies with 201 239 patients with mild and 17 415 patients with severe psoriasis reported that mild psoriasis was associated with an increased risk for MI (29%) and stroke (12%); severe psoriasis was associated with an even greater risk increase of 39%, 70%, and 56% for CV mortality, MI, and stroke, respectively. 12 Various CV risk factors have been linked to psoriasis and could partially explain the observed association between psoriasis and increased CV risk. Among 2.7 million individuals of which 300 000 patients had psoriasis, the odds ratio (OR) for hypertension among patients with psoriasis was 1.58 (95% confidence interval [CI]: 1.42-1.76) compared to the controls; patients with psoriatic arthritis had an even higher prevalence of hypertension (OR: 2.07; 95% CI: 1.41-3.04). 13 Masked and nocturnal hypertension were associated with increased CV risk and were more common among patients with psoriasis compared to healthy normotensive individuals as indicated by studies using ambulatory blood pressure monitoring. [14] [15] [16] [17] Furthermore, patients with psoriasis are less likely to achieve blood pressure control, while on antihypertensive treatment, and might require the use of more antihypertensive drugs compared to nonpsoriatic patients. 18, 19 Pooled data from 27 observational studies have also related the coexistence of diabetes with psoriasis (OR ¼ 1.59; 95% CI: 1.38-1.83 for diabetes in patients with psoriasis). 20 The severity of psoriasis was positively related with the prevalence of diabetes (OR: 1.53 and 1.97; 95% CI: 1.16-2.04 and 1.48-2.62; for patients with mild and severe psoriasis, respectively). 20 A meta-analysis from 16 studies of >200 000 patients with psoriasis suggested that patients with psoriasis were 1.66 times more likely to be obese compared to healthy controls. Furthermore, the risk for obesity was related to the severity of psoriasis; patients with mild and severe psoriasis were 1.46 and 2.23 times more likely to be obese. 21 Central obesity, an established CV risk factor, and its indices, such as waist circumference and waist-to-height ratio, were also found to have a positive relation with the presence of psoriasis. [22] [23] [24] Several studies support the increased incidence of dyslipidemia in patients with psoriasis. Among approximately 2 million patients, psoriasis was related even with a 5-fold risk increase for dyslipidemia compared to nonpsoriatic individuals. 25 Furthermore, data suggest that patients with severe psoriasis have higher odds for dyslipidemia compared to patients with mild forms of the disease. 26 A meta-analysis of 25 observational studies of almost 150 000 patients with psoriasis and more than half a million patients without psoriasis revealed an association between psoriasis and either current smoking (OR: 1.78; 95% CI: 1.52-2.06) or former smoking (OR: 1.62; 95% CI: 1.33-1.99). 27 In addition, an association between smoking and incidence of psoriasis was observed, which was dependent on smoking duration and intensity. 27 The relationship between smoking and psoriatic arthritis remains controversial. Both an inverse and a positive association have been reported, [28] [29] [30] possibly due to differences in study design and studied populations between conducted studies.
Erectile dysfunction (ED) is currently considered of vascular origin, and patients with ED are at increased risk for CV events and all-cause mortality. 31, 32 A recent systematic review of >20 000 patients with psoriasis and >80 000 controls demonstrated an increased prevalence of sexual dysfunction in patients (both genders) with psoriasis compared to controls. 33 Likewise, the prevalence of ED was 12.8% in patients with psoriasis compared to 8.7% in the general population in a very large cohort of Danish men (OR: 1.14; 95% CI: 1.08-1.20). 34 Of note, patients with mild psoriasis seem to be predisposed to more severe ED, 35 and depression seems to be a significant contributor to ED in psoriasis. 36, 37 Psoriasis and Vascular Damage: The Common Pathways and Markers of Vascular Disease
The increased incidence of CV risk factors in patients with psoriasis could partially explain the aggravated CV profile of these patients. However, it should be noted that the pathophysiological mechanisms of the disease share substantial similarities with that of atherosclerosis process. 38, 39 Cytokine dysregulation and inflammation in psoriasis result in abnormal dermal angiogenesis, inadequate cell-to-cell adhesion, and rapid keratinocyte proliferation, causing erythema and destruction of the normal skin barrier. 38 Atherosclerosis is typically characterized by systemic inflammation, cytokine dysregulation, and invasion of inflammatory cells as well, contributing in the development of atherosclerotic plaques. 26 Furthermore, T helper 1 and 17, regulatory T cells and natural killer T cells have been implicated in the pathogenetic pathways of both diseases. [39] [40] [41] Among other inflammatory molecules, interleukins 2, 6, 7, 8, 12, 15, 17, 18, 20 , and 23; tumor necrosis factor a; and interferon g participate in the expression of other chemokines and growth factors resulting in stimulation of inflammatory cells, endothelial dysfunction, and vascular smooth muscle proliferation that are all implicated in the pathophysiology of both psoriasis and atherosclerosis. 39, 42, 43 The common pathophysiological mechanisms of both diseases led research efforts to evaluate several markers of vascular damage and endothelial dysfunction in patients with psoriasis. [43] [44] [45] Comparisons between almost 2000 individuals with and without psoriasis showed increased common carotid intima-media thickness (cIMT) in patients with psoriasis compared to controls. 46 Other data support that patients with psoriasis have a higher prevalence and degree of coronary calcification score, and therefore coronary atherosclerosis, compared to controls. 47 In the same study, cIMT was significantly greater in patients with psoriasis than in controls. 47 Coronary flow reserve and hyperemic coronary diastolic peak flow velocity of the left anterior descending artery were significantly lower in the psoriasis than in the control group, whereas coronary flow reserve was inversely correlated with disease duration and the Psoriasis Area and Severity Index (PASI). 48, 49 Among several markers of vascular damage, pulse wave velocity (PWV), a marker of arterial stiffness, has proved to be of high CV prognostic value. 50, 51 An increase in aortic PWV per 1 m/s has been related to a 14% to 15% increase in the risk for CV events and all-cause mortality, respectively. 52 Overall, in patients with psoriasis, PWV was higher compared to healthy individuals. [53] [54] [55] Of note, a positive correlation was observed between PASI and PWV values. 54 Further evidence comes from a meta-analysis of >20 studies of approximately 2200 patients with psoriasis that were evaluated for the presence of endothelial dysfunction. 56 Patients with psoriasis or psoriatic arthritis had significantly increased arterial stiffness and cIMT, impaired endothelialdependent vasodilation, and decreased aortic elasticity compared to the general population. 45 Of note, serum levels of endocan, a novel marker of endothelial dysfunction, were elevated in patients with psoriasis compared to controls; in the psoriasis group, endocan levels significantly correlated with cIMT and high-sensitivity C-reactive protein (hsCRP). 44 In another study, both cIMT and hsCRP were associated with bilirubin levels in patients with psoriasis. 45 In this issue of the journal, Dattilo et al 57 assessed cardiac and vascular abnormalities in patients with psoriasis. The study compared 33 young patients with mild psoriasis (free of CV risk factors and overt CV disease) and 33 well-matched healthy volunteers. They found that traditional echocardiographic indices were similar between the 2 groups, while more modern echocardiographic techniques, such as the global longitudinal strain, were altered in patients with mild psoriasis and correlated with disease duration and age at diagnosis. 57 Moreover, arterial stiffness (assessed by carotid-femoral pulse wave velocity), a reliable index of vascular disease, was also altered in patients with psoriasis. 57 Dattilo et al 57 provided clinically meaningful data on the effect of mild psoriasis on the CV system, highlighting the importance of using modern echocardiographic indices to recognize subclinical heart disease. The study unveils the true effect of mild psoriasis in a younger group of patients, which is devoid of CV risk factors that might influence subclinical cardiac and vascular alterations. This is very important from the pathophysiologic point of view and represents a main advantage of the study. On the other hand, the same represents a main weakness of the study, since it limits the generalization of study findings, as the study does not evaluate the interaction with CV risk factors, which are very common in middle-aged patients. Furthermore, the investigators did not determine markers of damage of other target organs such as urinary albumin excretion, cIMT, ankle-brachial index, endothelial function, or inflammatory mediators, most of which may be altered in patients with psoriasis as described above. Finally, there were no ambulatory blood pressure measurements to exclude patients with masked hypertension, which may be associated with subclinical target-organ damage.
In conclusion, the increased CV risk of patients with psoriasis may be attributed to the common pathophysiological pathways underlying both psoriasis and atherosclerosis. The concomitant presence of other CV risk factors significantly aggravates the CV profile of patients with psoriasis. The study by Dattilo et al 57 provides meaningful data on diagnostic markers of early CV disease, highlighting the need for further research on markers of vascular damage extent in patients with psoriasis before the manifestation of overt CV disease.
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